Dorsey Asset Management’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$138M Buy
2,456,528
+179,958
+8% +$9.37M 8.82% 3
2026
Q1
$109M Buy
2,276,570
+17,101
+0.8% +$749K 8.7% 6
2025
Q4
$87.3M Sell
2,259,469
-90,980
-4% -$3.47M 7.59% 6
2025
Q3
$82.9M Buy
+2,350,449
New +$85.1M 7.45% 8

Other funds holding RPRX

Dorsey Asset Management's RPRX Position: Q2 2026 in Review

Dorsey Asset Management increased its Royalty Pharma (RPRX) stake by 7.9% in Q2 2026, buying an estimated $9.37M and bringing the position to 2,456,528 shares worth $138M. The position accounts for 8.82% of the portfolio, ranked #3.

Dorsey Asset Management first reported a position in RPRX in Q3 2025 and has held it in 4 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Dorsey Asset Management held 2,456,528 shares of Royalty Pharma worth $138M as of Q2 2026.
  • Dorsey Asset Management bought 179,958 Royalty Pharma shares in Q2 2026, an estimated $9.37M.
  • Royalty Pharma made up 8.82% of Dorsey Asset Management's portfolio in Q2 2026, its #3 holding.
  • Dorsey Asset Management first reported a position in Royalty Pharma in Q3 2025 and has held it in 4 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Dorsey Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.